The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | The impact of TP53 mutation on treatment approaches in MCL
Marcus Messmer, MD, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, comments on how TP53 mutation may impact treatment approaches in mantle cell lymphoma (MCL). Dr Messmer discusses the possibility of moving targeted therapies into earlier lines for this patient population, and the need for more clinical trials in this space. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
